

UGIS published or accepted peer reviewed articles (=432)

Liu Z, Zhang Y, **Lagergren J**, Li S, Li J, Zhou Z, Hu Z, Xie SH. Circulating sex hormone levels and risk of gastrointestinal cancer: systematic review and meta-analysis of prospective studies. *Cancer Epidemiol Biomark Prev* Apr 2023 (in press).

Asplund J, Mackenzie H, Markar SR, **Lagergren J**. Surgeon proficiency gain and survival after gastrectomy for gastric adenocarcinoma: A population-based cohort study. *Eur J Cancer* Mar 2023 (Online ahead of print).

Xie SH, Santoni G, Bottai M, Gottlieb Vedi E, Lagergren P, **Lagergren J**. Prediction of conditional survival in esophageal cancer in a population-based cohort study. *Int J Surg* Apr 2023 (Online ahead of print).

Bull A, Pucher PH, **Lagergren J**, Gossage JA. Impact of intra-pyloric botulinum toxin injection on delayed gastric emptying following esophagectomy: systematic review and meta-analysis. *Ann Esoph* Mar 2023 (Online ahead of print).

Kauppila JH, Markar S, Santoni G, Holmberg D, **Lagergren J**. Temporal changes in obesity-related medication after bariatric surgery compared to standard care for obesity – a population-based matched cohort study. *JAMA Surg* Feb 2023 (in press).

Abdulkarim D, Mattsson F, **Lagergren J**. Recent incidence trends of oesophago-gastric cancer in Sweden. *Acta Oncol* 2022;61:1490-8.

Kauppila JH, Mattsson F, **Lagergren J**. Impact of age on the treatment and survival in esophagogastric cancer. *Ann Surg Oncol* Jan 2023 (Online ahead of print).

Rosengren A, Söderberg M, Lundberg C, Lindgren M, Santosa A, Edqvist J, Åberg M, Gisslén M, Robertson J, Cronie O, Naveed S, **Lagergren J**, Brandén M, Björk J, Adiels M. COVID-19 in people of working age in Sweden in the first year of the pandemic: key factors for severe disease and death. A population-based cohort study. *Global Epidemiol* 2022;4:10009.

Pettersson AK, Santoni G, Yan J, Radkiewicz C, Xie S, Birgisson H, Ness-Jensen E, von Euler-Chelpin M, Kauppila JH, **Lagergren J**. Cohort profile: Nordic Helicobacter Pylori Eradication Project (NordHePEP). *Scand J Gastroenterol* Nov 2022;11;1-7. (Online ahead of print).

Markar S, Santoni G, Holmberg D, Kauppila JH, **Lagergren J**. Bariatric surgery volume by hospital and long-term survival: population-based NordOSCo data. *Br J Surg* 2023;110:177-82.

Holmberg D, **Lagergren J**. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma. *Foregut* Nov 2022 (in press).

Rahman R, Ludvigsson JF, von Seth E, **Lagergren J**, Bergquist A, Radkiewicz C. Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study. *Eur J Cancer* 2022;175:291-8.

Holmberg D, Mattsson F, Xie S, Ness-Jensen E, El-Serag HB, **Lagergren J**. Risk of gastric and esophageal adenocarcinoma following discontinuation of long-term proton pump inhibitor therapy in a population-based cohort study. *J Gastroenterol* 2022;57:942-51.

Leijonmarck W, Asplund J, Markar S, Mattsson F, **Lagergren J**. Weekday of gastrectomy and long-term survival in gastric adenocarcinoma. *EJSO* 2023;49:83-8.

Maret-Ouda J, Santoni G, Rosengren A, Xie SH, **Lagergren J**. Objectively confirmed gastroesophageal reflux disease and risk of atrial fibrillation: a population-based cohort study in Sweden. *Eur J Gastroenterol Hepatol* 2022;34:1116-20.

Wang X, Gharahkhani P, Levine DM, Fitzgerald RC, Gockel I, Corley DA, Risch HA, Bernstein L, Chow WH, Onstad L, Shaheen NJ, **Lagergren J**, Hardie LJ, Wu AH, Pharoah PD, Liu G, Anderson LA, Iyer PG, Gammon MD, Caldas C, Ye W, Barr H, Moayyedi P, Harrison R, Watson P, Attwood S, Chegwidden L, Love SB, MacDonald D, deCaestecker J, Prenen H, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weismüller J, Vashist Y, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Tomlinson I, Palles C, Jankowski J, Whiteman DC, MacGregor S, Schumacher J, Vaughan TL, Buas MF, Dai JY. eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 2022;31:1735-45.

Holmberg D, Santoni G, Kauppila J, Markar S, **Lagergren J**. Long-term survival after sleeve gastrectomy versus gastric bypass in a bi-national cohort study. *Diabetes Care* 2022;45:1981-6.

Rabbani S, Santoni S, **Lagergren J**, Xie S. Use of anti-androgenic 5 α -reductase inhibitors and risk of oesophageal and gastric cancer by histological type and anatomical sub-site. *Br J Cancer* 2022;127:892-7.

Rosengren A, Lundberg CE, Söderberg M, Santosa A, Edqvist J, Lindgren M, Åberg M, Gisslén M, Robertson J, Cronie O, Sattar N, **Lagergren J**, Brandén M, Björck J, Adiels M. Severe COVID-19 in people 55 and older during the first year of the pandemic in Sweden. *J Intern Med* 2022;292:641-53.

Hayami M, Ndegwa N, Lindblad M, Linder G, Hedberg J, Edholm D, Johansson J, **Lagergren J**, Lundell L, Nilsson M, Rouvelas I. Population-based cohort study from a prospective national registry: Better long-term survival in esophageal cancer after minimally invasive compared to open transthoracic esophagectomy. *Ann Surg Oncol* 2022;29:5609-21.

Lundberg C, Jamaly S, Adiels M, **Lagergren J**, Svensson J, Björck L, Rosengren A. Surgical treatment of obesity and excess risk of developing heart failure in a controlled cohort study. *ESC Heart Failure* 2022;9:1844-52.

Pucher PH, Coombes A, Evans O, Taylor J, Moore J, White A, **Lagergren J**, Baker C, Kelly M, Gossage JA, Dunn J, Zeki S, Byrne B, Andreyev J, Davies AR. Patient perspectives on key symptoms and preferences for follow-up after upper gastro-intestinal cancer surgery. *Supp Care Cancer* 2022;30:5269-75.

Holmberg D, Kauppila JH, Mattsson F, Asplund J, Leijonmarck W, Xie S, **Lagergren J**. Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma. *Gastric Cancer* 2022;25:652-8.

Lundberg E, Mattsson F, Lagergren P, **Lagergren J**. Life expectancy in survivors of oesophageal cancer compared to the background population. *Ann Surg Oncol* 2022;29:2805-11.

Moore JL, Davies AR, Santaolalla A, Van Hemelrijck M, Maisey N, **Lagergren J**, Gossage JA, Kelly M, Baker CR; Guy's and St. Thomas' Esophago-gastric Research Group. Clinical relevance of the tumor location-modified Laurén classification system for gastric cancer in a Western population. *Ann Surg Oncol* 2022;29:3911-20.

Ness-Jensen E, et al. Hypergastrinemia is not associated with increased mortality in gastric adenocarcinoma: A prospective population-based nested case-control study, the HUNT study. *Scand J Gastroenterol* 2022;57:558-65.

Kauppila J, Santoni G, Tao W, Lynge E, Jokinen J, Tryggvadóttir L, Ness-Jensen E, Pukkala E, von Euler-Chelpin M, **Lagergren J**. Risk factors for suicide after bariatric surgery in the Nordic countries. *Ann Surg* 2022;275:e410-e4.

Asplund J, Mattsson F, Plecka-Östlund M, Markar SR, **Lagergren J**. Surgeon and hospital volume of gastrectomy and survival in gastric adenocarcinoma. *Acta Oncol* 2022;61:425-32.

Moore J, Kumar S, Santaolalla A, Patel P, Kapiris M, Van Hemelrijk M, Maisey N, Hill M, **Lagergren J**, Gossage JA, Kelly M, Baker CR, Allum WH, Cunningham D, Davies AR. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - a comparison of the FLOT and 'MAGIC' regimens. *Eur J Cancer* 2022;163:180-8.

Zylstra J, Whyte GP, Beckmann K, Pate J, Santaolalla A, Gervais-Andre L, Russell B, Maisey N, Waters J, Tham G, **Lagergren J**, Green G, Kelly M, Baker C, Van Hemelrijck M, Goh V, Gossage J, Browning M, Davies A. Exercise prehabilitation during neo-adjuvant chemotherapy may enhance tumour regression in oesophageal cancer. *Br J Sports Med* 2022;56:402-9.

Zheng J, Gao Y, Xie SH, Santoni G, **Lagergren J**. Haemoglobin A1c and serum glucose levels and risk of gastric cancer: a systematic review and meta-analysis. *Br J Cancer* 2022;126:1100-7.

Bull A, Pucher PH, Maynard N, Underwood TJ, **Lagergren J**, Gossage JA. Nasogastric tube drainage and pyloric intervention after oesophageal resection: UK practice variation and effect on outcomes. *Eur J Surg Oncol* 2022;48:1033-8.

Kahrilas PJ, Savarino E, Anastasiou F, Bredenoord A, Corsetti M, **Lagergren J**, Mendive J, Nelson S, Roman S, Zerbib F, Hungin P. The tapestry of reflux symptoms: translation of current knowledge into clinical practice. *Br J Gen Pract* 2021;71:470-3.

Holmberg D, Santoni G, von Euler-Chelpin MC, Färkkilä M, Kauppila JH, Maret-Ouda J, Ness-Jensen E, **Lagergren J**. Incidence and mortality in upper gastrointestinal cancer after negative endoscopy for gastroesophageal reflux disease. *Gastroenterology* 2022;162:431-8.e4.

Bull A, Pucher PH, **Lagergren J**, Gossage JA. Chest drainage after oesophageal resection: A systematic review. *Dis Esophagus* 2022;12;35:doab069.

Xie S, Santoni G, **Lagergren J**. Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study. *Br J Cancer* 2022;126:129-33.

Maret-Ouda J, Santoni G, Rosengren A, Xie SH, **Lagergren J**. Proton pump inhibitor and clopidogrel use after percutaneous coronary intervention and risk of major cardiovascular events. *Cardiovasc Drug Ther* 2022;36:1121-8.

Aboul-Enein MS, Knight W, Wulaningsih W, Foley DM, Dellaportas JD, Zylstra J, Baker CR, Kelly M, Smyth E, **Lagergren J**, Maisey N, Allum WH, Gossage JA, Cunningham D, Davies AR. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma. *J Surg Oncol* 2021;124:1296-1305.

Dunn JM, Reyhani A, Santaolalla A, Zylstra J, Gimson E, Pennington M, Baker C, Kelly M, Van Hemelrijck M, **Lagergren J**, Zeki SS, Gossage JA, Davies AR. Transition from esophagectomy to endoscopic therapy for early esophageal cancer. *Dis Esophagus* 2022;35:doab047.

Gottlieb-Vedi E, Kauppila J, Mattsson F, The Finnish National Esophago-Gastric cancer Cohort (FINEGO) group, Lindblad M, Nilsson M, Lagergren P, Rouvelas I, **Lagergren J**. Long-term survival in esophageal cancer after minimally invasive esophagectomy compared to open esophagectomy. *Ann Surg* 2022;276:e744-e748.

Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Färkkilä M, Lyng E, Pukkala E, Romundstad P, Tryggvadóttir L, von Euler-Chelpin M, **Lagergren J**. Laryngeal and pharyngeal squamous cell carcinoma after antireflux surgery in the five Nordic countries. *Ann Surg* 2022;276:e79-e85.

Maret-Ouda J, Santoni G, Wahlin K, Artama M, Brusselaers N, Färkkilä M, Lyng E, Mattsson F, Ólafsdóttir GH, Pukkala E, Romundstad P, Tryggvadóttir L, Euler-Chelpin MV, **Lagergren J**. Esophageal adenocarcinoma after antireflux surgery and medication in a cohort study from the five Nordic countries. *Ann Surg* 2021;274:e535-40.

Markar S, Santoni S, Maret-Ouda J, Färkkilä M, Lyng E, Pukkala E, Ness-Jensen E, von Euler-Chelpin M, **Lagergren J**. Hospital volume of anti-reflux surgery in relation to endoscopic and surgical re-interventions. *Ann Surg* 2021;274:e1138-43.

Lundberg CE, Björck L, Adiels M, **Lagergren J**, Rosengren A. Risk of myocardial infarction, ischemic stroke, and mortality in patients who undergo gastric bypass for obesity compared with non-operated obese patients and population controls. *Ann Surg* 2021;277:275-83.

Gottlieb-Vedi E, Kauppila J, Mattsson F, Hedberg J, Johansson J, Edholm D, Lagergren P, Nilsson M, FINEGO group, **Lagergren J**. Extent of lymphadenectomy and long-term survival in esophageal cancer. *Ann Surg* Jun 2021 (Online ahead of print).

Shore R, Yu J, Ye W, **Lagergren J**, Rutegård M, Akre O, Stattin P, Lindblad M. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. *Sci Rep* 2021;11:13486.

Kalff MC, Gottlieb-Vedi E, Verhoeven RHA, van Laarhoven HWM, Xie S, **Lagergren J**, Gisbertz SS, Markar SR, van Berge Henegouwen MI. Presentation, treatment and prognosis of esophageal carcinoma in a nationwide comparison of Sweden and the Netherlands. *Ann Surg* 2021;274:743-50.

Zheng J, Santoni G, Xie S, **Lagergren J**. Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study. *Br J Cancer* 2021;125:277-83.

Yanes M, Santoni G, Maret-Ouda J, Markar S, Ness-Jensen E, Kauppila J, Färkillä M, Lyng E, Pukkala E, Tryggvadóttir L, von Euler-Chelpin M, **Lagergren J**. Mortality, reoperation and hospital stay within 90 days of primary and secondary antireflux surgery in a population-based multinational study. *Gastroenterology* 2021;160:2283-90.

Bott RK, Smyth EC, Cunningham D, Gossage JA, Baker CR, Kelly M, Maisey N, Allum WH, **Lagergren J**, Davies AR. Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. *Acta Oncol* 2021;60:672-80.

Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Färkillä M, Lyng E, Pukkala E, Romundstad P, Tryggvadóttir L, von Euler-Chelpin M, **Lagergren J**. Survival after antireflux surgery versus medication in patients with reflux oesophagitis or Barrett's oesophagus: a multinational cohort study. *Br J Surg* 2021;108:864-70.

Asplund J, Leijonmarck W, Mattsson F, Gottlieb Vedi E, **Lagergren J**. Prognosis after surgery for gastric adenocarcinoma in the Swedish gastric cancer surgery study (SWEGASS). *Acta Oncol* 2021;60:513-20.

Wang Q, Ness-Jensen E, Santoni G, Xie S, **Lagergren J**. Development and validation of a risk prediction model for esophageal squamous cell carcinoma using cohort studies. *Am J Gastroenterol* 2021;116:683-91.

Xie S, Santoni G, Mälberg K, Lagergren P, **Lagergren J**. Prediction model of long-term survival after esophageal cancer surgery. *Ann Surg* 2021;273:933-9.

Ness-Jensen E, Bringeland EA, Mattsson F, Mjønes P, **Lagergren J**, Grønbech JE, Waldum HL, Fossmark R. Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: a prospective population-based nested case-control study. *Int J Cancer* 2021;15;148:1879-86.

Xie S, Ness-Jensen E, Langseth H, Gislefoss R, Mattsson F, **Lagergren J**. Pre-diagnostic circulating levels of sex hormones and survival in esophageal adenocarcinoma. *Int J Cancer* 2021;148:905-913.

Markar S, Santoni G, Maret-Ouda J, **Lagergren J**. Hospital volume of esophageal cancer surgery in relation to outcomes from primary anti-reflux surgery. *Dis Esophagus* 2021;34(1):doaa075.

Cheng Z, Johar A, Gottlieb-Vedi E, Nilsson M, **Lagergren J**, Lagergren P. Impact of comorbidity on reoperation or death within 90 days of surgery for oesophageal cancer. *BJS Open* 2021;5(1):zraa035.

Dighe SG, Chen J, Yan L, He Q, Gharahkhani P, Onstad L, Levine DM, Palles C, Ye W, Gammon MD, Iyer PG, Anderson LA, Liu G, Wu AH, Dai JY, Chow WH, Risch HA, **Lagergren J**, Shaheen NJ, Bernstein L, Corley DA, Prenen H, deCaestecker J, MacDonald D, Moayyedi P, Barr H, Love SB, Chegwidden L, Attwood S, Watson P, Harrison R, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weismüller J, Gockel I, Vashist Y, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Ambrosone CB, Moysich KB, MacGregor S, Tomlinson I, Whiteman DC, Jankowski J, Schumacher J, Vaughan TL, Madeleine MM, Hardie LJ, Buas MF. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. *Carcinogenesis* 2021;42:369-77.

Maret-Ouda J, Markar SR, **Lagergren J**. Gastroesophageal reflux disease. *JAMA* 2020;324:2536-47.

Dong J, Maj C, Tsavachidis S, Ostrom QT, Gharahkhani P, Anderson LA, Wu AH, Ye W, Bernstein L, Borisov O, Schröder J, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, May A, Gerges C, Anders M, Venerito M, Schmidt T, Izbicki JR, Hölscher AH, Schumacher B, Vashist Y, Neuhaus H, Rösch T, Knapp M, Krawitz P, Böhmer A, Iyer PG, Reid BJ, **Lagergren J**, Shaheen NJ, Corley DA, Gockel I, Fitzgerald RC, Stomach and Oesophageal Cancer Study (SOCS) consortium, Cook MB, Whiteman DC, Vaughan TL, Schumacher J, Thrift AP. Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterology* 2020;159:2065-2076.e1.

Xie S, Rabbani S, Ness-Jensen E, **Lagergren J**. Circulating levels of inflammatory and metabolic biomarkers and risk of esophageal adenocarcinoma and Barrett's esophagus: systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2020;29:2109-18.

Yanes M, Santoni G, Maret-Ouda J, Ness-Jensen E, Färkkilä M, Lynge E, Pukkala E, Romundstad P, Tryggvadóttir L, von Euler-Chelpin M, **Lagergren J**. Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study European Journal of Cancer. *Eur J Cancer* 2020;138:80-8.

Ness-Jensen E, Gottlieb-Vedi E, Santoni G, Lindam A, Pedersen N, **Lagergren J**. Mortality in gastro-oesophageal reflux disease in a population-based nationwide cohort study of Swedish twins. *BMJ Open* 2020;10:e037456.

Bott RK, Beckmann K, Zylstra J, Wilkinson MJ, X Knight WRC, Baker CR, Kelly M, Maisey N, Waters J, Van Hemelrijck M, Smyth EC, Allum WH, Cunningham D, **Lagergren J**, Gossage JA, Davies AR. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. *Br J Surg* 2020;107:1801-10.

Tao W, Artama M, von Euler-Chelpin M, Ljung R, Lynge E, Ólafsdóttir GH, Pukkala E, Romundstad P, Ness-Jensen E, Talbäck M, Tryggvadóttir L, **Lagergren J**. Cancer risk after bariatric surgery in the Nordic countries. *Obes Surg* 2020;30:3761-7.

Lagergren J, Bottai M, Santoni G. Patient age and survival after surgery for esophageal cancer. *Ann Surg Oncol* 2021;28:159-66.

- Xie S, Chen H, **Lagergren J**. Causes of death in patients diagnosed with gastric adenocarcinoma in 1970-2014 in Sweden: A population-based study. *Cancer Sci* 2020;111:2451-9.
- Doorackers E, **Lagergren J**, Santoni G, Engstrand L, Brusselaers N. Helicobacter pylori eradication treatment and the risk of Barrett's esophagus and esophageal adenocarcinoma. *Helicobacter* 2020;25(3):e12688.
- Backemar L, Johar A, Wikman A, Zylstra J, Gossage J, Davies A, **Lagergren J**, Lagergren P. The influence of comorbidity on health-related quality of life after esophageal cancer surgery. *Ann Surg Oncol* 2020;27:2637-45.
- Xie S, Lagergren P, Mälberg K, Andersson G, **Lagergren J**. Geographical variations in the incidence of oesophageal cancer in Sweden. *Scand J Gastroenterol* 2020;55:258-64.
- Kauppila JH, Santoni G, Tao W, Lyng E, Koivukangas V, Tryggvadóttir L, Ness-Jensen E, Romundstad P, Pukkala E, von Euler-Chelpin M, **Lagergren J**. Reintervention or mortality within 90 days of bariatric surgery: population-based cohort study. *Br J Surg* 2020;107:1221-30.
- Xie S, Fang R, Huang M, Dai J, Thrift AP, Anderson LA, Chow WH, Bernstein L, Gammon MD, Risch HA, Shaheen NJ, Reid BJ, Wu AH, Iyer PG, Liu G, Corley DA, Whiteman DC, Caldas C, Pharoah PD, Hardie LJ, Fitzgerald RC, Shen H, Vaughan TL, **Lagergren J**. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. *Clin Gastroenterol Hepatol* 2020;18:2701-2709.
- Maret Ouda J, Santoni G, Artama M, Ness-Jensen E, Svensson JF, von Euler-Chelpin M, **Lagergren J**. Aspiration pneumonia after antireflux surgery among neurologically impaired children with GERD. *J Pediatr Surg* 2020;S0022-3468;30934-0.
- Wang Q, Santoni G, Ness-Jensen E, **Lagergren J**, Xie S. Association between Metformin use and risk of esophageal squamous cell carcinoma in a population-based cohort study. *Am J Gastroenterol* 2020;115:73-8.
- Markar SR, **Lagergren J**. Surgical and surgeon-related factors related to long-term survival in esophageal cancer: a review. *Ann Surg Oncol* 2020;27:718-23.
- Holmberg D, Mattsson F, **Lagergren J**. Endoscopy for gastroesophageal reflux disease and survival in esophageal adenocarcinoma. *Int J Cancer* 2020;147:93-9.
- Xie S, Ness-Jensen E, Rabbani S, Langseth H, Gislefoss RE, Mattsson F, **Lagergren J**. Circulating sex hormone levels and risk of esophageal adenocarcinoma in a prospective study in men. *Am J Gastroenterol* 2020;115:216-23.
- Markar SR, Arhi C, Wiggins T, Vidal-Diez A, Karthikesalingam A, Darzi A, **Lagergren J**, Hanna GB. Re-intervention after anti-reflux surgery for gastro-oesophageal reflux disease in England. *Ann Surg* 2020;271:709-15.
- Tao W, Artama M, von Euler-Chelpin M, Ljung R, Lyng E, Ólafsdóttir GH, Pukkala E, Romundstad P, Ness-Jensen E, Talbäck M, Tryggvadottir L Hull M, **Lagergren J**. Colon and rectal cancer risk after bariatric surgery in a multi-country Nordic cohort study. *Int J Cancer* 2020;147:728-35.

Knight WRC, Yip C, Wulaningsih W, Jacques A, Griffin N, Zylstra J, Van Hemelrijck M, Maisey N, Gaya A, Baker CR, Kelly M., Gossage J A, **Lagergren J**, Landau D, Goh V, Davies AR, Ngan S, Qureshi A, Deere H, Green M, Chang F, Mahadeva U, Gill-Barman B, George S, Dunn J, Zeki S, Meenan J, Hynes O, Tham G, Iezzi C. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. *BJS Open* 2019; 3:767–76.

Zheng J, Xie S, Santoni G, **Lagergren J**. Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. *Br J Cancer* 2019; 121:877-82.

Sverdén E, Agréus L, Dunn JM, **Lagergren J**. Peptic ulcer disease. *BMJ* 2019;367:15495.

Brusselsaers N, **Lagergren J**, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. *Cancer Epidemiol* 2019;62:101585.

Holmberg D, Ness-Jensen E, Mattsson F, **Lagergren J**. Adherence to clinical guidelines for Barrett's esophagus. *Scand J Gastroenterol* 2019;54:945-52.

Zheng J, Rutegård M, Santoni G, Wallner B, Johansson I, Sund M, Xie S, **Lagergren J**. Prediabetes and diabetes in relation to risk of gastric adenocarcinoma. *Br J Cancer* 2019;120:1147–52.

Helminen O, Kytö V, Kauppila JH, Gunn J, **Lagergren J**, Sihvo E. Anastomotic strictures after minimally invasive and open esophagectomy for cancer: a population-based study from Finland and Sweden. *BJS Open* 2019;10;3:634-40.

Holmberg D, Santoni G, Xie S, **Lagergren J**. Gastric bypass surgery in the treatment of gastro-oesophageal reflux symptoms. *Aliment Pharmacol Ther* 2019;50:159-66.

Wang Q, **Lagergren J**, Xie S. Prediction of individuals at high absolute risk of oesophageal squamous cell carcinoma. *Gastrointest Endoscopy* 2019;89:726-32.

Kauppila J, Tao W, Santoni G, von Euler-Chelpin M, Lynge E, Tryggvadóttir L, Ness-Jensen E, Romundstad P, Pukkala E, **Lagergren J**. Effects of obesity surgery on overall and disease-specific mortality in a 5-country, population-based study. *Gastroenterology* 2019;157:119-27.

Gottlieb-Vedi E, Mattsson F, Lagergren P, **Lagergren J**. Annual hospital volume of surgery for gastrointestinal cancer in relation to prognosis. *Eur J Surg Oncol* 2019;45:1839-46.

Helminen O, Kauppila JH, Kytö V, Gunn J, **Lagergren J**, Sihvo E. Preoperative esophageal stenting and short-term outcomes of surgery for esophageal cancer in a population-based study from Finland and Sweden. *Dis Esophagus* 2019;0:1–6.

Gottlieb-Vedi E, Kauppila JH, Malietzis G, Nilsson M, Markar SR, **Lagergren J**. Long-term survival after minimally invasive and open esophagectomy for esophageal cancer: a systematic review and meta-analysis. *Ann Surg* 2019;270:1005-17.

Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study (SOCS) Consortium, Iyer PG, Reid BJ, **Lagergren J**, Shaheen NJ, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L,

Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP. No association between vitamin D status and risk of Barrett's esophagus or esophageal adenocarcinoma-a Mendelian Randomization Study. *Clin Gastroenterol Hepatol* 2019;17:2227-35.e1.

Xie S, Santoni G, Mattsson F, Ness-Jensen E, **Lagergren J**. Cohort profile: The Swedish Prescribed Drugs and Health Cohort (SPREDH). *BMJ Open* 2019;9:e023155.

Kilander C, Konings P, **Lagergren J**, Sadr-Azodi O, Brusselaers N. Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden. *Acta Oncol* 2019;1-6.

Sverdén E, Mattsson F, Lu Y, Lindström D, Sondén A, **Lagergren J**. Transcatheter arterial embolisation compared with surgery for uncontrolled peptic ulcer bleeding. *Ann Surg* 2019;269:304-9.

Holmberg D, Ness-Jensen E, Mattsson F, **Lagergren J**. Clinical prediction model for tumor progression in Barrett's esophagus. *Surg Endosc* 2019;33:2901-8.

Kunzmann AT, Canadas Garre M, Thrift AP, McMenamin ÚC, Johnston BT, Cardwell CR, Anderson LA, Spence AD, **Lagergren J**, Xie S, Smyth L, McKnight AJ, Coleman HG. Information on genetic variants does not increase identification of individuals at risk of esophageal adenocarcinoma compared to clinical risk factors. *Gastroenterology* 2019;156:43-5.

Gottlieb Vedi E, Markar S, MacKenzie H, Lagergren P, **Lagergren J**. Surgeon volume and surgeon age in relation to proficiency gain curves for prognosis following surgery for esophageal cancer. *Ann Surg Oncol* 2019;25:497-505.

Markar SR, Vidal-Diez A, Sounderajah V, Mackenzie H, Hanna GB, Thompson M, Holt P, **Lagergren J**, Karthikesalingam A. A population-based cohort study examining the risk of abdominal cancer after endovascular abdominal aortic aneurysm repair. *J Vasc Surg* 2019;69:1776-85.e2.

Kauppila J, Wahlin K, Lagergren P, **Lagergren J**. Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma. *Int J Cancer* 2019;144:1284-91.

Kleverbro F, Johar A, **Lagergren J**, Lagergren P. Outcomes of nutritional jejunostomy in the curative treatment of esophageal cancer. *Dis Esophagus* 2019;32.

Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, **Lagergren J**, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. *Ann Oncol* 2018;29:2356-62.

Xie S, **Lagergren J**. Risk factors for oesophageal cancer. *Best Pract Res Clin Gastroenterol* 2018;36-37:3-8.

Sverdén E, Markar S, Agreus L, **Lagergren J**. Acute upper gastrointestinal bleeding. *BMJ* 2018;363:k4023.

Toxopeus E, van der Schaaf M, van Lanschot J, **Lagergren J**, Lagergren P, van der Gaast A, Wijnhoven B. Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). *Ann Surg Oncol* 2018;25:2441-8.

Kilander C, **Lagergren J**, Ljung R, Sadr-Azodi O. The population-based incidence and mortality of biliary tract cancer in Sweden. *Cancer Epidemiol* 2018;56:14-20.

Asplund J, Kauppila J, Mattsson F, **Lagergren J**. Survival trends in gastric adenocarcinoma: a population-based study in Sweden. *Ann Surg Oncol* 2018;25:2693-702.

Zheng J, Xie S, Santoni G, **Lagergren J**. Population-based cohort study of diabetes mellitus and mortality in gastric adenocarcinoma. *Br J Surg* 2018;105:1799-806.

Brusselaers N, Tamimi R, Konings P, Adami HO, **Lagergren J**. Different menopausal hormone regimens and risk of breast cancer. *Ann Oncol* 2018;29:1771-6.

Brusselaers N, **Lagergren J**. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. *BMJ Open* 2018;8:e021869.

Mackenzie H, Markar SR, Askari A, Faiz O, Hull M, Purkayastha S, Moller H, **Lagergren J**. Obesity surgery and risk of cancer. *Br J Surg* 2018;105:1650-7.

Markar S, Arhi C, Leusink A, Vidal-Diez A, Karthikesalingam A, Darzi A, **Lagergren J**, Hanna GB. The influence of anti-reflux surgery on esophageal cancer risk in England – national population-based cohort study. *Ann Surg* 2018;268:861-7.

Davies A, Dellaportas D, Zylstra J, Baker CR, Wulaningsih W, Hemelrijck MV, Maisey N, Allum WH, Gossage JA, **Lagergren J**, Cunningham D, Green M. Lymph node regression predicts survival following neo-adjuvant chemotherapy in oesophageal adenocarcinoma. *Br J Surg* 2018;105:1639-49.

Kauppila J, Mattsson F, **Lagergren J**. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. *BMJ Open* 2018;8:e021495.

Wang QL, Xie SH, Wahlin K, **Lagergren J**. Global time trends in the incidence of esophageal squamous cell carcinoma. *Clin Epidemiol* 2018;10:717-28.

Lagergren F, Xie S, Mattsson F, **Lagergren J**. Updated incidence trends in cardia and non-cardia gastric adenocarcinoma in Sweden. *Acta Oncol* 2018;57:1173-8.

Xie S, Medefelt N, Ness-Jensen E, **Lagergren J**. Assessing the feasibility of targeted screening for oesophageal adenocarcinoma based on individual risk assessment in a population-based cohort study in Norway (The HUNT Study). *Am J Gastroenterol* 2018;113:829-35.

Kunzmann AT, Thrift AP, Cardwell CR, **Lagergren J**, Xie S, Johnston BT, Anderson LA, Busby J, McMenamin UC, Spence AD, Coleman HG. Model for identifying individuals at risk for esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2018;16:1229-36.

Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC, Corley DA, Shaheen NJ, **Lagergren J**, Hardie LJ, Reid BJ, Iyer PG, Risch HA, Caldas C, Caldas I, Pharoah PD, Liu G, Gammon MD, Chow WH, Bernstein L, Bird NC, Ye W, Wu AH, Anderson LA, MacGregor S, Whiteman DC, Vaughan TL, Thrift AP. Interactions between genetic variants and environmental factors affect risk of esophageal adenocarcinoma and Barrett's esophagus. *Clin Gastroenterol Hepatol* 2018;16:1598-606.

Knight W, Zylstra J, Wulaningsih W, Van Hemelrijck M, Landau D, Maisey N, Baker C, Gossage J, **Lagergren J**, Davies A. Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma. *BJS Open* 2018;2:229-37.

Kauppila JH, Wahlin K, Lagergren P, **Lagergren J**. University hospital status and surgeon volume and risk of reoperation following surgery for esophageal cancer. *Eur J Surg Oncol* 2018;44:632-7.

Markar S, Wiggins T, Antonowicz S, Chin ST, Romano A, Nikolic K, Evans B, Cunningham D, Mughal M, **Lagergren J**, Hanna GB. Breath test for diagnosing cancer of the oesophagus or stomach: A multi-centre study. *JAMA Oncol* 2018;4:970-6.

Brusselsaers N, Engstrand L, **Lagergren J**. Maintenance proton pump inhibitor therapy and risk of oesophageal cancer. *Cancer Epidemiol* 2018;53:172-7.

Doorackers E, **Lagergren J**, Engstrand L, Brusselsaers N. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. *Gut* 2018;67:2092-6.

Aravani A, Downing A, Thomas JD, **Lagergren J**, Morris EJA, Hull MA. Obesity surgery and risk of colorectal and other obesity-related cancers: An English population-based cohort study. *Cancer Epidemiol* 2018;53:99-104.

Kauppila JH, Wahlin K, Lagergren P, **Lagergren J**. Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer. *Sci Rep* 2018;8:446.

Sverdén E, Brusselsaers N, Wahlin K, **Lagergren J**. Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study. *Gastrointest Endosc* 2018;88:242-50.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, **Lagergren J**, Shaheen NJ, Corley DA, Fitzgerald RC. Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP. Determining risk of Barrett's esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. *Gastroenterology* 2018;154:1273-81.

Xie S, **Lagergren J**. Social group disparities in the incidence and prognosis of oesophageal cancer. *United European Gastroenterol J* 2018;6:343-8.

Knight WRC, Zylstra J, Van Hemelrijck M, Griffin N, Jacques AET, Maisey N, Baker CR, Gossage JA, **Lagergren J**, Davies AR. Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. *BJS Open* 2018;1:182-90.

Kauppila J, Ringborg C, Johar A, **Lagergren J**, Lagergren P. Health-related quality of life after gastrectomy, esophagectomy and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. *Gastric Cancer* 2018;21:533-41.

Kauppila JH, Helminen O, Kytö V, Gunn J, **Lagergren J**, Sihvo E. Short-term outcomes following minimally invasive and open esophagectomy: a population-based study from Finland and Sweden. *Ann Surg Oncol* 2018;25:326-32.

Ness-Jensen E, Gottlieb-Vedi E, Wahlin K, **Lagergren J**. All-cause and cancer-specific mortality in GORD in a population-based cohort study (the HUNT study). *Gut* 2018;67:209-15.

Kauppila J, Johar A, Gossage J, Davies A, **Lagergren J**, Lagergren P. Health-related quality of life after open transhiatal and transthoracic oesophagectomy for cancer. *Br J Surg* 2018;105:230-6.

Coleman HG, Xie SH, **Lagergren J**. The epidemiology of esophageal adenocarcinoma. *Gastroenterology* 2018;154:390-405.

Markar SR, Johar A, Maisey N, Lagergren P, **Lagergren J**. Complications during neoadjuvant therapy and prognosis following surgery for esophageal cancer. *Dis Esophagus* 2018;1;31.

Markar S, Mackenzie H, Lagergren P, **Lagergren J**. Surgeon age in relation to prognosis after esophageal cancer resection. *Ann Surg* 2018;268:100-5.

Davies AR, Gossage JA, Zylstra J, Baker CR, Dellaportas D, **Lagergren J**, Findlay JM, Puccetti F, El Lakis M, Drummond R, Dutta S, Mera A, Van Hemelrijck M, Forshaw MJ, Maynard ND, Allum WH, Lowe D, Mason RC. A comparison of the left thoraco-abdominal and Ivor-Lewis esophagectomy. *Dis Esoph* 2018;1;31.

Kauppila JH, Wahlin K, **Lagergren J**. Gastrectomy compared to oesophagectomy for Siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival. *Sci Rep* 2017;7:17783.

Brusselsaers N, Wahlin K, Engstrand L, **Lagergren J**. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. *BMJ Open* 2017;7:e017739.

Ness-Jensen E, **Lagergren J**. Tobacco smoking, alcohol consumption and gastro-oesophageal reflux disease. *Best Pract Res Clin Gastroenterol* 2017;31:501-8.

Brusselsaers N, **Lagergren J**. The Charlson Comorbidity Index in Registry-based Research. *Methods Inf Med* 2017;56:401-6.

Tao W, Artama M, von Euler-Chelpin M, Konings P, Ljung R, Lyng E, Ólafsdóttir GH, Pukkala E, Romundstad P, Tryggvadóttir L, Wahlin K, **Lagergren J**. Data Resource Profile: The Nordic Obesity Surgery Cohort (NordOSCo). *Int J Epidemiol* 2017;46:1367-7g.

Maret-Ouda J, Wahlin K, El-Serag HB, **Lagergren J**. Association between laparoscopic antireflux surgery and recurrence of gastroesophageal reflux. *JAMA* 2017;318:939-46.

Li W, Xie S, Tse L, **Lagergren J**. Digitalis use and lung cancer risk by histological type in men. *Int J Cancer* 2017;141:1981-6.

Simin J, Tamimi R, **Lagergren J**, Adami HO, Brusselaers N. Menopausal hormone therapy and cancer risk: An overestimated risk? *Eur J Cancer* 2017;84:60-8.

Lagergren J, Mattsson F, Lagergren P. Prognosis following cancer surgery during holiday periods. *Int J Cancer* 2017;141:1971-80.

Smyth E, **Lagergren J**, Fitzgerald RC, Lordick F, Shah M, Lagergren P, Cunningham D. Oesophageal cancer. *Nat Rev Dis Primers* 2017;3:17048.

Hynes O, Anandavadivelan P, Gossage J, Johar A, **Lagergren J**, Lagergren P. The impact of pre- and post-operative weight loss and body mass index on prognosis in patients with oesophageal cancer. *Eur J Surg Oncol* 2017;43:1559-65.

Persson CE, Björck L, **Lagergren J**, Lappas G, Giang KW, Rosengren A. Risk of heart failure in obese patients with and without bariatric surgery in Sweden - a registry-based study. *J Card Fail* 2017;23:530-7.

Noorani A, Bornschein J, Lynch AG, Secrier M, Achilleos A, Eldridge M, Bower L, Weaver JM, Crawte J, Ong CA, Shannon N, MacRae S, Grehan N, Nutzinger B, O'Donovan M, Hardwick R, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium., Elliott RF, Edwards PAW, Li X, Chettouh H, Contini G, Gregson E, Zeki S, Smith L, Abdullahi Z, de la Rue R, Miremadi A, Malhotra S, Smith ML, Davies J, Crichton C, Carroll N, Safranek P, Hindmarsh A, Sujendran V, Turkington R, Hayes SJ, Ang Y, Preston SR, Oakes S, Bagwan I, Save V, Skipworth RJE, Hupp TR, O'Neill JR, Tucker O, Beggs A, Taniere P, Underwood TJ, Noble F, Owsley J, Barr H, Shepherd N, Old O, **Lagergren J**, Gossage J, Davies A, Chang F, Zylstra J, Sanders G, Berrisford R, Harden C, Bunting D, Lewis M, Cheong E, Kumar B, Parsons SL, Soomro I, Kaye P, Lovat L, Haidry R, Eneh V, Igali L, Scott M, Sothi S, Suortamo S, Lishman S. A comparative analysis of whole genome sequencing of oesophageal adenocarcinoma pre- and post-chemotherapy. *Genome Res* 2017;27:902-12.

Xie S, Rabbani S, Petrick J, Cook M, **Lagergren J**. Racial and ethnic disparities in the incidence of esophageal cancer in the United States, 1992-2013. *Am J Epidemiol* 2017;186:1341-51.

Lagergren J, Mattsson F, Lagergren P. [Weekday of cancer surgery in relation to prognosis](#). *Br J Surg* 2017;104:1735-43.

Maret-Ouda J, Wahlin K, et al, **Lagergren J**. Cohort profile: The Nordic Antireflux Surgery Cohort (NordASCo). *BMJ Open* 2017;7:e016505.

Wang Q, Xie S, Li W, **Lagergren J**. Smoking cessation and risk of esophageal cancer by histological type: A systematic review and meta-analysis. *J Natl Cancer Inst* 2017 Dec 1;109(12).

Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. *Lancet* 2017;390:2383-96.

Doorackers E, **Lagergren J**, Gajulapuri V, Callens S, Engstrand L, Brusselsaers N. Helicobacter pylori eradication in the Swedish population. *Scand J Gastroenterol* 2017;52:678-85.

Xie S, Mattsson F, **Lagergren J**. Incidence trends in oesophageal adenocarcinoma: An updated analysis in Sweden. *Cancer Epidemiol* 2017;47:114-7.

Xie SH, Jernberg T, Mattsson F, **Lagergren J**. Digitalis use and risk of gastrointestinal cancers: a nationwide population-based cohort study. *Oncotarget* 2017;23;8:34727-35.

Rutegård M, Lagergren P, Johar A, Rouvelas I, **Lagergren J**. The prognostic role of celiac node metastasis after resection for distal esophageal cancer. *Sci Rep* 2017;7:43744.

Xie S, Wahlin K, **Lagergren J**. Cause of death in patients diagnosed with oesophageal cancer in Sweden: a population-based study. *Oncotarget* 2017;11;8:51800-9.

Hellstadius Y, **Lagergren J**, Zylstra J, Gossage J, Davies A, Hultman CM, Lagergren P, Wikman A. A longitudinal assessment of psychological distress after oesophageal cancer surgery. *Acta Oncol* 2017;56:746-52.

Maret-Ouda J, Tao W, Wahlin K, **Lagergren J**. Nordic registry-based cohort studies – possibilities and pitfalls when combining Nordic registry data. *Scand J Publ Health* 2017;45(17_suppl):14-19.

Holmberg D, Ness-Jensen E, Mattsson F, El-Serag HB, **Lagergren J**. Risk of esophageal adenocarcinoma in individuals with Barrett's esophagus. *Eur J Cancer* 2017;75:41-6.

Brusselsaers N, Maret-Ouda J, Konings P, El-Serag HB, **Lagergren J**. Menopausal hormone therapy and the risk of esophageal and gastric cancer. *Int J Cancer* 2017;140:1693-9.

Tao W, Hull M, Konings P, Mattsson F, Adami HO, **Lagergren J**. Colorectal cancer prognosis following obesity surgery in a population-based cohort study. *Obes Surg* 2017;27:1233-9.

Maret-Ouda J, Tao W, Mattsson F, Brusselsaers N, Hashem B El-Serag, **Lagergren J**. Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. *Surg Obes Rel Dis* 2017;13:28-34.

Xie S, **Lagergren J**. A possible link between famine exposure in early life and future risk of gastrointestinal cancers: Implications from age-period-cohort analysis. *Int J Cancer* 2017;140:636-45.

Maret Ouda J, **Lagergren J**. Mortality from secondary antireflux surgery. *Am J Surg* 2017;213:1160-2.

Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, **Lagergren J**, Fitzgerald RC, Ye W, Calda C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah P, Liu G, Iyer P, Reid BJ, Corley DA, Risch HA, Murray LJ, Chow WH, Whiteman DC, Vaughan TL, Madeleine MM. Germline variation in inflammation-related pathways and risk of Barrett's esophagus and esophageal adenocarcinoma. *Gut* 2017;66:1739-47.

Xie S, **Lagergren J**. Using the Lorenz curve to assess the feasibility of targeted screening for esophageal adenocarcinoma. *Epidemiology* 2017;28:e11-12.

Lagergren J, Mattsson F, Davies A, Lindblad M, Lagergren P. Lymphadenectomy and risk of early reoperation or mortality shortly after esophageal cancer surgery. *Sci Rep* 2016;6:36092.

Schandl A, **Lagergren J**, Johar A, Lagergren P. Health-related quality of life 10 years after oesophageal cancer surgery. *Eur J Cancer* 2016;69:43-50.

Maret-Ouda J, El-Serag H, **Lagergren J**. Opportunities for prevention of esophageal adenocarcinoma. *Cancer Prev Res* 2016;9:828-34.

Kauppila JH, **Lagergren J**. The surgical management of esophago-gastric junctional cancer. *Surg Oncol* 2016;4:394-400.

Garcia E, et al. Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. *Sci Rep* 2016;6:32417.

Xie S, **Lagergren J**. Time trends in the incidence of oesophageal cancer in Asia: variations across populations and histological types. *Cancer Epidemiol* 2016;44:71-6.

Markar S, Wahlin K, Mattsson F, Lagergren P, **Lagergren J**. Surgery during holiday periods and prognosis in oesophageal cancer: a population-based nationwide Swedish cohort study. *BMJ Open* 2016;6:e013069.

Schandl A, Johar A, **Lagergren J**, Lagergren P. Lymphadenectomy and health related quality of life after oesophageal cancer surgery. *BMJ Open* 2016;6:e012624.

Gharakhani P, Fitzgerald RC, Vaughan TL, Tomlinson I, Gockel I, Palles C, Buas MF, May A, Gerges C, Anders A, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, deCaestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, **Lagergren J**, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. *Lancet Oncol* 2016;17:1363-73.

Lagergren K, Wahlin K, Mattsson F, Aldersen D, **Lagergren J**. Haemochromatosis and risk of luminal gastrointestinal cancer. *Int J Cancer* 2016;139:1740-3.

Markar S, Wahlin K, Lagergren P, **Lagergren J**. University hospital status and prognosis following surgery for esophageal cancer. *Eur J Surg Oncol* 2016;42:1191-5.

Møller H, Riaz SP, Holmberg L, Jakobsen E, **Lagergren J**, Page R, Peake MD, Pearce N, Purushotham A, Sullivan R, Vedsted P, Luchtenborg M. High lung cancer surgical procedure volume is associated with shorter length of stay and lower risks of re-admission and death: National cohort analysis in England. *Eur J Cancer* 2016;64:32-43.

Lagergren J, Mattsson F, Lagergren P. Weekday of surgery for oesophageal cancer and risk of poor short-term outcomes in a population-based study. *BMJ Open* 2016;263:1133-7.

Doorackers E, **Lagergren J**, Engstrand L, Brusselsaers N. Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies. *J Natl Cancer Inst* 2016;14;108(9).

Xie S, **Lagergren J**. Global assessment of the male predominance in oesophageal adenocarcinoma. *Oncotarget* 2016;21;7:38876-83.

Lindam A, Ness-Jensen E, Jansson C, Nordenstedt H, Hveem K, **Lagergren J**. Gastroesophageal reflux and sleep problems: direction of association in a population-based longitudinal cohort study, the HUNT study. *Sleep* 2016;39:1421-7.

Martin L, **Lagergren J**, Blomberg J, Johar A, Bosaeus I, Lagergren P. Phase angle as a prognostic marker after percutaneous endoscopic gastrostomy (PEG) in a prospective cohort study. *Scand J Gastroenterol* 2016;51:1013-6.

Kilander C, **Lagergren J**, Ljung R, Mattsson F, Sadr-Azodi O. Exogenous estrogen and the risk of biliary tract cancer - a population-based study in a cohort of Swedish men treated for prostate cancer. *Acta Oncol* 2016;55:846-50.

Maret Ouda J, Yanes M, Konings P, Brusselsaers N, **Lagergren J**. Mortality from laparoscopic antireflux surgery in a nationwide cohort of the working-age population. *Br J Surg* 2016;103:863-70.

Markar SR, Mackenzie H, Johar A, Lagergren P, Hanna GB, **Lagergren J**. Surgical proficiency gain and survival after esophagectomy for cancer. *J Clin Oncol* 2016;34:1528-36.

Markar SR, **Lagergren J**, Hanna GB. Research protocol for a diagnostic study of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer. *BMJ Open* 2016;6;6:e009139.

Lagergren F, Mattsson F, **Lagergren J**. Validation of the date of surgery for oesophageal cancer in the Swedish patient registry. *Acta Oncol* 2016;55:925-6.

Xie S, **Lagergren J**. A model for predicting individuals' absolute risk of oesophageal adenocarcinoma: moving towards tailored screening and prevention. *Int J Cancer* 2016;138:2813-9.

Tao W, Holmberg D, Naslund E, Naslund I, Mattsson F, **Lagergren J**, Ljung R. Validation of obesity surgery data in the Swedish National Patient Registry and Scandinavian Obesity Surgery Registry (SOReg). *Obes Surg* 2016;26:1750.

Xie S, Lagergren J. The male predominance in esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2016;14:338-347.

Lagergren J, Andersson G, Talbäck M, Drefahl S, Bihagen E, Härkönen J, Feychting M, Ljung R. Marital status, education and income in relation to risk of oesophageal and gastric cancer by histological type and site. *Cancer* 2016;122:207-12.

Ek WE, Lagergren K, Cook M, Wu AH, Abnet CC, Levine D, Chow WH, Bernstein L, Risch HA, Shaheen NJ, Bird NC, Corley DA, Hardie LJ, Fitzgerald RC, Gammon M, Romero Y, Liu G, Ye W, Vaughan TL, MacGregor S, Whitman DC, Westberg L, Lagergren J. Polymorphisms in genes of relevance for androgen pathways and risk of Barrett's esophagus and esophageal adenocarcinoma. *Int J Cancer* 2016;138:1146-52.

Hellstadius Y, Lagergren J, Zylstra J, Gossage J, Davies A, Hultman CM, Lagergren P, Wikman A. Prevalence and predictors of anxiety and depression among oesophageal cancer patients prior to surgery. *Dis Esophagus* 2016;8:1128-34.

Maret-Ouda J, Lagergren J, Brusselaers N. Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis. *Ann Surg* 2016;263:251-7.

Lu Y, Shivappa N, Lin Y, Lagergren J, Hébert JR. Diet-related inflammation and oesophageal cancer by histological type: a nationwide case-control study in Sweden. *Eur J Nutr* 2016;55:1683-94.

Lagergren J, Mattsson F, Zylstra J, Chang F, Gossage J, Mason R, Lagergren P, Davies A. Extent of lymphadenectomy during oesophageal cancer surgery in relation to survival. *JAMA Surg* 2016;151:32-9.

Sverden E, Mattsson F, Sonden A, Leidsköld T, Lu Y, Lagergren J. Risk factors for marginal ulcer after gastric bypass surgery for obesity. *Ann Surg* 2016;263:733-7.

Ness-Jensen E, Hveem K, El-Serag H, Lagergren J. Lifestyle intervention and gastroesophageal reflux disease. Review. *Clin Gastroenterol Hepatol* 2016;14:175-182.

Lagergren J, Mattsson F, Lagergren P. Weekday of oesophageal cancer surgery and its relation to prognosis. *Ann Surg* 2016;263:1133-7.

Lee E, Stram DO, Ek W, Onstad LE, MacGregor S, Buas M, Gharahkhani P, Ye W, Lagergren J, Bird NC, Romero Y, Shaheen NJ, Murray LJ, Hardie LJ, Gammon MD, Chow WH, Risch HA, Corley DA, Reid BJ, Levine DM, Abnet C, Whitman DC, Bernstein L, Vaughan TL, Wu AH. Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk. *Cancer Epidemiol Biomark Prev* 2015;24:1801-3.

Lin Y, Ness-Jensen E, Hveem K, Lagergren J, Lu Y. Metabolic syndrome and esophageal and gastric cancer. *Cancer Causes Control* 2015;26:1825-34.

Lu Y, García Rodríguez LA, Malgerud L, González-Pérez A, Martín-Pérez M, Lagergren J, Bexelius T. New-onset type 2 diabetes, anti-diabetic medications and risk of pancreatic cancer: a case-control study nested within the THIN cohort. *Br J Cancer* 2015;113:1607-14.

Lindam A, Kendall BJ, Thrift AP, Macdonald GA, O'Brien S, **Lagergren J**, Whiteman D. Symptoms of obstructive sleep apnea, gastroesophageal reflux and the risk of Barrett's esophagus in a population-based case-control study. *Plos One* 2015;10:e0129836.

James Y. Dai, Jean de Dieu Tapsoba, Matthew F. Buas, Lynn Onstad, David M. Levine, Harvey A. Risch, Wong-Ho Chow, Geoffrey Liu, Leslie Bernstein, Weimin Ye, **Lagergren J**, Nigel C. Bird, Yvonne Romero, Liam J. Murray, Douglas A. Corley, Nicholas J. Shaheen, Anna H. Wu, Marilie D. Gammon, Brian J. Reid, Laura J. Hardie, David C. Whiteman, Thomas L. Vaughan. A newly identified susceptibility locus near FOXP1 modifies the association of gastroesophageal reflux with Barrett's esophagus. *Cancer Epidemiol Biomark Prev* 2015;24:1739-47.

Lagergren K, Ek W, Levine D, Chow WH, Bernstein L, Casson AG, Risch HA, Shaheen NJ, Bird NC, Reid BJ, Corley DA, Hardie LJ, Wu AH, Vaughan TL, MacGregor S, Whiteman D, Westberg L, Nyrén O, **Lagergren J**. Polymorphisms in genes of relevance for estrogen and oxytocin pathways and risk of Barrett's esophagus and esophageal adenocarcinoma. *Plos One* 2015;10:e0138738.

Maret-Ouda J, Brusselsaers N, Lagergren **J**. What is the most effective treatment for severe gastro-oesophageal reflux disease? *BMJ* 2015; 24;350.

Backemar L, Lagergren P, Johar A, **Lagergren J**. Impact of co-morbidity on mortality after oesophageal cancer surgery. *Br J Surg* 2015;102:1097-105.

Backemar L, Lagergren P, Djärv T, Johar A, Wikman A, **Lagergren J**. Co-morbidities and risk of complications after surgery for oesophageal cancer: A nationwide cohort study in Sweden. *World J Surg* 2015;39:2282-8.

Brusselsaers N, Mattsson F, Lindblad M, **Lagergren J**. Association between education level and prognosis after esophageal cancer surgery: A population-based cohort study. *PLoS One* 2015;10:e0121928.

Brusselsaers N, Vall A, Mattsson F, **Lagergren J**. Tumour staging of oesophageal cancer in the Swedish Cancer Registry: A nationwide validation study. *Acta Oncol* 2015;54:903-8.

Jokinen J, Mattsson F, Lagergren K, **Lagergren J**, Ljung R. Suicide attempt and future risk of cancer - a nationwide cohort study in Sweden. *Cancer Causes Control* 2015; 6:501-9.

Doorakers E, Konings P, Mattsson F, **Lagergren J**, Brusselsaers N. Early complications following oesophagectomy for cancer in relation to long-term healthcare utilisation: A prospective population-based cohort study. *PLoS One* 2015;10:e0121080.

Kilander C, Mattsson F, Lu Y, **Lagergren J**, Omid Sadr-Azodi. Reproductive factors and risk of biliary tract cancer: a population-based study. *Acta Oncol* 2015;54:1152-8.

Rutegård M, Lagergren P, Johar A, **Lagergren J**. Time shift in early postoperative mortality after oesophagectomy for cancer. *Ann Surg Oncol* 2015;22(9):3144-9.

Jansson C, Oh JK, Martinsen JI, **Lagergren J**, Plato N, Kjaerheim K, Pukkala E, Sparén P, Tryggvadóttir L, Weiderpass E. Occupation and risk of oesophageal adenocarcinoma and squamous-cell carcinoma: the Nordic Occupational Cancer study. *Int J Cancer* 2015;137:590-7.

Lagergren J. Oesophageal cancer in 2014: Advances in curatively intended treatment. *Nat Rev Gastroenterol Hepatol* 2015;12:74-5.

Schaaf Mv, Johar A, Wijnhoven B, Lagergren P, **Lagergren J.** Extent of lymph node removal during esophageal cancer surgery and survival. *J Natl Cancer Inst* 2015;107.

Wikman A, Ljung R, Johar A, Hellstadius Y, **Lagergren J,** Lagergren P. Psychiatric morbidity and survival following oesophageal cancer surgery: a population-based cohort study. *J Clin Oncol* 2015;33:448-54.

Derogar M, Sadr-Azodi O, Lagergren P, **Lagergren J.** Splenic injury during resection for esophageal cancer: Risk factors and consequences. *Ann Surg* 2015;261:111-6.

Tao W, Plecka-Östlund M, Lu Y, Mattsson F, **Lagergren J.** Causes and risk factors for mortality within 1 year after obesity surgery in a population-based cohort study. *Surg Obes Rel Dis* 2015;11:399-40.

Hellstadius Y, Lagergren P, Johar A, Hultman C, **Lagergren J,** Wikman A. Aspects of emotional functioning following oesophageal cancer surgery in a population-based cohort study. *Psycho-Oncol* 2015;24:47-53.

Lin Y, Yngve A, **Lagergren J,** Lu. A dietary pattern rich in lignans, quercetin and resveratrol decreases the risk of oesophageal cancer. *Br J Nutr* 2014;112:2002-9.

Sverdén E, Sondén A, Leinsköld T, **Lagergren J,** Lu Y. Minimal versus definitive surgery in managing refractory peptic ulcer bleeding. *Dig Surg* 2014;31:276-82.

Davies AR, Gossage JA, Zylstra J, Mattsson F, **Lagergren J,** Maisey N, Smyth E, Cunningham D, Allum WH, Mason RC. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. *J Clin Oncol* 2014;32:2983-90.

Brusselsaers N, Mattsson F, Johar A, Wikman A, Lagergren P, **Lagergren J,** Ljung R. Marital status and survival after esophageal cancer surgery: A population-based nationwide cohort study in Sweden. *BMJ Open* 2014;4:e005418.

Wang Q, Ljung R, **Lagergren J,** Lu Y. Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding. *BMC Pharmacol Toxicol* 2014;15:22.

Lagergren K, **Lagergren J,** Brusseleers N. Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis. *Int J Cancer* 2014;135:2183-90.

van der Schaaf M, Johar A, Derogar M, Rutegård M, Gossage J, Mason RM, Lagergren P, **Lagergren J.** Reoperation after oesophageal cancer surgery in relation to long-term survival: a population-based cohort study. *BMJ Open* 2014;4:e004648.

Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, Gossage JA, **Lagergren J,** Allum WH, Mason RC. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. *Br J Surg* 2014;101:511-7.

Ljung R, Sennerstam R, Mattsson F, Auer G, **Lagergren J**. Anticoagulant treatment at time of needle biopsy in relation to breast cancer stage at diagnosis. *Int J Cancer* 2014;135:238-41.

Lu Y, Oddsberg J, Martling A, **Lagergren J**. Reproductive history and risk of colorectal adenocarcinoma: a nationwide nested case-control study in Sweden. *Epidemiology* 2014;25:595-604.

Brusselaers N, Ljung R, Mattsson F, Johar A, Wikman A, Lagergren P, **Lagergren J**. Education level and survival after oesophageal cancer surgery: a prospective population-based cohort study. *BMJ Open* 2013;3:e003754.

Davies AR, Pillai A, Sinha P, Sandhu H, Adeniran A, Mattsson F, Choudhury A, Forshaw MJ, Gossage JA, **Lagergren J**, Allum WH, Mason RC. Factors associated with early recurrence and death after esophagectomy for cancer. *J Surg Oncol* 2014;109:459-64.

Brusselaers N, Mattsson F, **Lagergren J**. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. *Gut* 2014;63:1393-400.

Ness-Jensen E, Lindam A, **Lagergren J**, Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: A prospective population-based cohort study: The HUNT study. *Am J Gastroenterol* 2014;109:171-7.

Fitzgerald RC, di Pietro M, Ragnath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, **Lagergren J**, Moayyedi P, Lyrtzopoulos G, Caestecker J. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. *Gut* 2014;63:7-42.

Kilander C, Mattsson F, Ljung R, **Lagergren J**, Omid Sadr-Azodi. Systematic underreporting of the population-based incidence of pancreatic and biliary tract cancers. *Acta Oncol* 2014;53:822-9.

van der Schaaf MK, Tilanus HW, van Lanschot JJB, Johar A, Lagergren P, **Lagergren J**, Wijnhoven BPL. The influence of pre-operative weight loss on post-operative course after esophageal cancer resection. *J Thor Cardiovasc Surg* 2014;147:490-5.

Lagergren J, Mattsson F, Nyrén O. Gastroesophageal reflux does not alter effects of body mass index on risk of esophageal adenocarcinoma. *Clin Gastroenterol Hepatol* 2014;12:45-51.

Tao W, **Lagergren J**. Clinical management of obese patients with cancer. *Nat Rev Clin Oncol* 2013;10:519-33.

Bexelius TS, Ljung R, Mattsson F, **Lagergren J**. Cardiovascular disease and risk of acute pancreatitis in a population-based study. *Pancreas* 2013;42:1011-5.

van der Schaaf M, Johar A, Lagergren P, Rouvelas I, Gossage J, Mason R, **Lagergren J**. Surgical prevention of reflux after oesophagectomy for cancer. *Ann Surg Oncol* 2013;20:3655-61.

Lagergren J, Mattsson F, Lagergren P. Survey of the clinical implementation of a new antibiotic prophylaxis regimen for percutaneous endoscopic gastrostomy. *BMJ Open* 2013;28;3.

Coupland VH, **Lagergren J**, Lüchtenborg M, Jack RH, Allum W, Holmberg L, Hanna GB, Pearce N, Møller H. Hospital volume, proportion resected and mortality from oesophageal and gastric cancer: a population-based study in England, 2004-2008. *Gut* 2013;62:961-6.

Ljung R, Drefahl S, Andersson G, **Lagergren J**. Socio-demographic and geographical factors in esophageal and gastric cancer mortality in Sweden. *PLoS One* 2013;8:e62067.

Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. *CA Cancer J Clin* 2013;63:232-48.

Forssell L, Cnattingius S, Bottai M, Edstedt Bonamy AK, **Lagergren J**, Agréus L, Akre O. Risk of oesophageal adenocarcinoma among individuals born preterm or small for gestational age. *Eur J Cancer* 2013;49:2207-13.

Backemar L, Djärv T, Wikman A, Johar A, Ross P, Lagergren P, **Lagergren J**. The role of diabetes and other co-morbidities on survival after esophageal cancer surgery in a population-based study. *Am J Surg* 2013;206:539-43.

Plecka Östlund M, Marsk R, Stockeld D, **Lagergren J**, Rasmussen F, Näslund E. Increased admission alcohol dependence after gastric by-pass surgery compared with restrictive bariatric surgery. *JAMA Surg* 2013;148:374-7.

Löfdahl H, Lu Y, Lagergren P, **Lagergren J**. Risk factors for developing esophageal adenocarcinoma after antireflux surgery. *Ann Surg* 2013;257:579-82.

Sadr-Azodi O, Mattsson F, Sjöberg Belius T, **Lagergren J**, Ljung R. Oral glucocorticoid use increases the risk of acute pancreatitis – a population-based nested case-control study. *JAMA Intern Med* 2013;173:444-9.

Derogar M, Hull MA, Kant P, Östlund M, Lu Y, **Lagergren J**. Increased risk of colorectal cancer after obesity surgery in a retrospective cohort study. *Ann Surg* 2013;258:983-8.

Lagergren K, Mattsson F, **Lagergren J**. Abdominal fat and male excess of esophageal adenocarcinoma. *Epidemiology* 2013;24:465-6.

Forssell L, Cnattingius S, Bottai M, Edstedt Bonamy AK, **Lagergren J**, Agréus L, Akre O. Risk of Barrett's esophagus among individuals born preterm or small for gestational age. *Clin Gastroenterol Hepatol* 2013;11:790-4.

Ness-Jensen E, Lindam A, **Lagergren J**, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: The HUNT Study. *Am J Gastroenterol* 2013;108:376-82.

Lagergren K, Lindam A, **Lagergren J**. Dietary proportions of carbohydrates, fat, and proteins and risk of oesophageal cancer by histological type. *PLoS One* 2013;8(1):e54913.

Derogar M, Sadr-Azodi O, Johar A, Lagergren P, **Lagergren J**. Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. *J Clin*

Oncol 2013;31:551-7.

Lu Y, Sverdén E, Ljung R, Söderlundh C, **Lagergren J**. Use of non-steroidal anti-inflammatory drugs and proton pump inhibitors in correlation with incidence, recurrence and fatality of peptic ulcer bleeding. *BMJ Open* 2013;3:e002056.

Lin Y, Wolk A, Håkansson N, **Lagergren J**, Lu Y. Dietary intake of lignans and risk of esophageal and gastric adenocarcinoma: a cohort study in Sweden. *Cancer Epidemiol Biomarkers Prev* 2013;22:308-12.

Lagergren P, Johar A, **Lagergren J**. Validation of the reflux scale in EORTC QLQ-OES18. *Eur J Cancer* 2013;49:1097-103.

Bexelius TS, Blomberg J, Lu YX, Håkansson HO, Möller P, Nordgren CE, Arnelo U, **Lagergren J**, Lindblad M. Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial. *World J Gastrointest Endosc* 2012;4:506-12.

Lindam A, Nordenstedt H, Jansson C, Pedersen N, **Lagergren J**. Gastroesophageal reflux disease and sleep problems in a population-based twin study. *PLoS One* 2012;7:e48602.

Lu Y, Oddsberg J, Martling A, **Lagergren J**. Reproductive history and risk of small bowel cancer by histologic type: a population-based study. *Cancer Causes Control* 2012;23:2041-6.

Löfdahl HE, Du J, Näsman A, Andersson E, Rubio C, Lu Y, Ramqvist T, Dalianis T, **Lagergren J**, Dahlstrand H. Prevalence of human papillomavirus (HPV) in oesophageal squamous cell carcinoma in relation to anatomical site of the tumour. *PLoS One* 2012;7(10):e46538.

Coupland VH, **Lagergren J**, Konfortion J, Allum W, Mendall MA, Hardwick RH, Linklater KM, Møller H, Jack RH. Ethnicity in relation to incidence of oesophageal and gastric cancer in England. *Br J Cancer* 2012;107:1908-14.

Lin Y, Lu Y, Håkansson N, Peñalvo Garcia JL, **Lagergren J**, Adlercreutz H, Wolk A. Validation of food frequency questionnaire-based assessment of dietary lignans compared with serum enterolactone in Swedish women. *Br J Nutr* 2012;1-8.

Forssell L, Cnattingius S, Bottai M, **Lagergren J**, Ekblom A, Akre O. Risk of esophagitis among individuals born preterm or small for gestational age. *Clin Gastroenterol Hepatol* 2012;10:1369-75.

Djärv T, Wikman A, Nordenstedt H, Johar A, **Lagergren J**, Lagergren P. Physical activity, obesity and gastroesophageal reflux disease in the general population. *World J Gastroenterol Hepatol* 2012;18:3710-4.

Lagergren J, Mattsson F. Diverging trends in recent population-based survival rates in oesophageal and gastric cancer. *PLoS One* 2012;7:e41352.

Lu Y, **Lagergren J**. Reproductive factors and risk of oesophageal adenocarcinoma, a population-based nested case-control study in Sweden. *Br J Cancer* 2012;107:564-9.

Rutegård M, Charonis K, Lu Y, Lagergren P, **Lagergren J**, Rouvelas I. Population-based esophageal cancer survival after surgery without neoadjuvant therapy: An update. *Surgery* 2012;152:903-10.

Bodén R, Bexelius TS, Mattsson F, **Lagergren J**, Lindblad M, Ljung R. Antidopaminergic drugs and acute pancreatitis: a population based study. *BMJ Open* 2012;2(3).

Ljung R, Rück C, Mattsson F, Bexelius T, **Lagergren J**, Lindblad M. Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: a Swedish population-based case-control study. *J Clin Psychopharmacol* 2012;32:336-40.

Lagergren J, Lindam A, Mason RM. Gastric stump cancer after distal gastrectomy for benign gastric ulcer in a population-based study. *Int J Cancer* 2012;131:1048-52.

Lin Y, Yngve A, **Lagergren J**, Lu Y. Dietary intake of lignans and risk of adenocarcinoma of the esophagus and gastroesophageal junction. *Cancer Causes Control* 2012;23:837-44.

Rutegård M, Charonis K, Lagergren P, Rouvelas I, Mason R, **Lagergren J**. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. *Eur J Surg Oncol* 2012;38:555-61.

Blomberg J, **Lagergren J**, Martin L, Mattsson F, Lagergren P. Complications after percutaneous endoscopic gastrostomy in a prospective study. *Scand J Gastroenterol* 2012;47:737-42.

Lagergren J, Lindam A. Increased risk of laryngeal and pharyngeal cancer after gastrectomy for ulcer disease in a population-based cohort study. *Br J Cancer* 2012;106:1342-5.

Winberg H, Lindblad M, **Lagergren J**, Dahlstrand H. Barrett's esophagus: Risk factors and chemoprevention – an update. *Scand J Gastroenterol* 2012;47:397-406.

Plecka Östlund M, Wenger U, Ljung R, Botha A, Mattsson F, Ebrahim F, **Lagergren J**. Population-based study of the need for cholecystectomy after obesity surgery. *Br J Surg* 2012;99:864-9.

Lu Y, Fröbom R, **Lagergren J**. Incidence patterns of small bowel cancer in a population-based study in Sweden: Increase in duodenal adenocarcinoma. *Cancer Epidemiol* 2012;36:58-63.

Nordenstedt H, Mattsson F, El-Serag H, **Lagergren J**. Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. *Br J Cancer* 2012;106:1011-5.

Ness-Jensen E, Lindam A, **Lagergren J**, Hveem K. Changes in prevalence, incidence and spontaneous loss of gastro-oesophageal reflux symptoms: a prospective population-based cohort study, the HUNT study. *Gut* 2012;61:1390-7.

van der Schaaf, **Lagergren J**, Lagergren P. Persisting symptoms after intrathoracic anastomotic leak following oesophagectomy for cancer. *Br J Surg* 2012;99:95-9.

Oddsberg J, Lu Y, **Lagergren J**. Aspects of esophageal atresia in a population-based setting: incidence, mortality, and cancer risk. *Pediatr Surg Int* 2012;28:249-57.

Lagergren J, Lindam A. The risk of esophageal adenocarcinoma after gastrectomy for peptic ulcer disease. *Eur J Cancer* 2012;48:749-52.

Ljung R, **Lagergren J**, Bexelius TS, Mattsson F, Lindblad M. Increased risk of acute pancreatitis among tetracycline users in a Swedish population-based case-control study. *Gut* 2012;61:873-6.

Ljung R, Jansson C, Nordenstedt H, Martin L, Lagergren P, **Lagergren J**. Twelve tips for conducting a post-graduate course on study design and study protocol writing for the medical profession. *Med Teach* 2012;34:25-9.

Rutegård M, Lagergren P, Rouvelas I, **Lagergren J**. Intrathoracic anastomotic leakage and mortality after esophageal cancer resection: a population-based study. *Ann Surg Oncol* 2012;19:99-103.

Lagergren J, Mattsson F. Cholecystectomy and risk of laryngeal and pharyngeal cancer. *Int J Cancer* 2012;130:2211-4.

Lagergren J. Influence of obesity on the risk of esophageal disorders. *Nat Rev Gastroenterol Hepatol* 2011;8:340-7.

Ljung, Sjöberg Bexelius T, Martin L, **Lagergren J**. Oral disease and risk of pancreatic cancer. *Epidemiology* 2011;22:749-50.

Ljung R, Lu Y, **Lagergren J**. High concomitant use of interacting drugs and low use of gastroprotective drugs among NSAID users in an unselected elderly population: A nationwide register-based study. *Drugs Aging* 2011;28:469-76.

Lagergren J, Mattsson F, El-Serag H, Nordenstedt H. Increased risk of hepatocellular carcinoma after cholecystectomy. *Br J Cancer* 2011;105:154-6.

Rutegård M, Lagergren P, Nordenstedt H, **Lagergren J**. Oesophageal adenocarcinoma: the new epidemic in men? *Maturitas* 2011;69:244-8.

Lagergren J, Mattsson F. Cholecystectomy as a risk factor for esophageal adenocarcinoma. *Br J Surg* 2011;98:1133-7.

Lagergren J, Jansson C, Lu Y. Motor vehicle exposure and risk of esophageal adenocarcinoma. *Eur J Cancer* 2011;47:1446-9.

Ljung R, Martin L, **Lagergren J**. Oral disease and risk of esophageal and gastric cancer in a nationwide nested case-control study in Sweden. *Eur J Cancer* 2011;47:2128-32.

Östlund M, Marsk R, Rasmussen F, **Lagergren J**, Näslund E. Morbidity and mortality before and after bariatric surgery for morbid obesity compared with the general population. *Br J Surg* 2011;98:811-6.

Löfdahl HE, Lane A, Lu Y, Lagergren P, Harvey RF, Blazeby JM, **Lagergren J**. Increased population prevalence of reflux and obesity in the United Kingdom compared with Sweden: a potential explanation for the difference in incidence of oesophageal adenocarcinoma. *Eur J Gastroenterol Hepatol* 2011;23:128-32.

Blomberg J, Lagergren P, Martin L, Mattsson F, **Lagergren J**. Albumin and C-reactive protein levels predict short-term mortality after percutaneous endoscopic gastrostomy in a prospective cohort study. *Gastrointest Endosc* 2011;73:29-36.

Lagergren J, Lagergren P. Esophageal cancer. *BMJ* 2010;341:c6280.

Oddsberg J, Lu Y, **Lagergren J**. Maternal diabetes and risk of esophageal atresia. *J Pediatr Surg* 2010;45:2004-8.

Lagergren J, Mattsson F. No further increase in the incidence of esophageal adenocarcinoma in Sweden. *Int J Cancer* 2011;129:513-6.

Rouvelas I, **Lagergren J**. The impact of volume on outcomes after oesophageal cancer surgery. *ANZ J Surg* 2010;80:634-41.

Sjödahl K, **Lagergren J**. Epidemiological aspects of gastric adenocarcinoma: Are predictive diagnostics and targeted preventive measures possible? *EPMA Journal* 2010;1:461-71.

Rutegård M, Nordenstedt H, Lu Y, **Lagergren J**, Lagergren P. Sex-specific exposure prevalence of established risk factors for oesophageal adenocarcinoma. *Br J Cancer* 2010;103:735-40.

Lin Y, **Lagergren J**, Lu Y. Dietary acrylamide intake and risk of esophageal cancer in a population-based case-control study in Sweden. *Int J Cancer* 2011;128:676-81.

Blomberg J, Lagergren P, Martin L, Mattsson F, **Lagergren J**. Novel approach to antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG): randomised controlled trial. *BMJ* 2010;341:c3115.

Östlund MP, Lu Y, **Lagergren J**. Risk of obesity-related cancer after obesity surgery in a population-based cohort study. *Ann Surg* 2010;252:972-6.

Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, Corley DA, Sharp L, **Lagergren J**. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. *Eur J Cancer* 2010;46:2067-76.

Lagergren J, Ye W, Lagergren P, Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. *Gastroenterology* 2010;138:1297-1301.

Blomberg J, Wenger U, **Lagergren J**, Arnelo U, Agustsson T, Johnsson E, Toth E, Lagergren P. Antireflux stent versus conventional stent in the palliation of distal esophageal cancer. A randomized multicenter clinical trial. *Scand J Gastroenterol* 2010;45:208-16.

Jansson C, Jeding K, **Lagergren J**. Job strain and risk of esophageal and cardia cancers. *Cancer Epidemiol* 2009; 33:473-5.

Chandanos E, **Lagergren J**. The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen. *Eur J Cancer* 2009;45:3149-55.

Lu Y, **Lagergren J**, Eloranta S, Lambe M. Childbearing and salivary gland cancer: a population-based nested case-control study. *Epidemiology* 2009;20:780-2.

Jansson C, Nordenstedt H, Wallander M, Johansson S, Johnsen R, Hveem K, **Lagergren J**. A population-based study showing an association between gastroesophageal reflux disease and sleep problems. *Clin Gastroenterol Hepatol* 2009;7:960-5.

El-Serag HB, **Lagergren J**. Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. *Gastroenterology* 2009;136:1155-7.

Rutegård M, **Lagergren J**, Rouvelas I, Lagergren P. Surgeon volume is a poor proxy for skill in esophageal cancer surgery. *Ann Surg* 2009;249:256-61.

Nordenstedt H, **Lagergren J**. Environmental factors in the etiology of gastroesophageal reflux disease. *Expert Rev Gastroenterol Hepatol* 2008;2:93-103.

Lagergren J. Any role for endoscopy screening or surveillance for esophageal adenocarcinoma among persons with GERD? *Gastrointest Endosc* 2008;68:856-8.

Oddsberg J, Jia C, Nilsson E, Ye W, **Lagergren J**. Maternal tobacco smoking, obesity, and low socioeconomic status during early pregnancy in the etiology of esophageal atresia. *J Pediatr Surg* 2008;43:1791-5.

Löfdahl H, Lu Y, **Lagergren J**. Sex-specific risk factor profile in esophageal adenocarcinoma. *Br J Cancer* 2008;99:1506-10.

Chandanos E, Rubio CA, Lindblad M, Jia C, Tsolakis AV, Warner M, Gustafsson JA, **Lagergren J**. Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. *Gastric Cancer* 2008;11:168-74.

Oddsberg J, Jia C, Nilsson E, Ye W, **Lagergren J**. Influence of maternal parity, age and ethnicity on risk of esophageal atresia in the infant in a population-based study. *J Pediatr Surg* 2008;43:1660-5.

Chandanos E, **Lagergren J**. Oestrogen and the enigmatic male predominance of gastric cancer. *Eur J Cancer* 2008;44:2397-403.

Sundelöf M, **Lagergren J**, Ye W. Surgical factors influencing outcomes in patients resected for cancer of the esophagus or gastric cardia. *World J Surg* 2008;32:2357-65.

Sjödahl K, Jia C, Vatten L, Nilsen TI, Hveem K, **Lagergren J**. Salt and gastric adenocarcinoma: a population-based cohort study in Norway. *Cancer Epidemiol Biomarkers Prev* 2008;17:1997-2001.

Djärv T, **Lagergren J**, Blazeby JM, Lagergren P. Long-term health-related quality of life following surgery for esophageal cancer. *Br J Surg* 2008;95:1121-6.

Sundelöf M, **Lagergren J**, Ye W. Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. *Eur J Cancer* 2008;44:1566-71.

Chandanos E, Lindblad M, Rubio C, Warner M, Gustafsson JA, **Lagergren J**. Tamoxifen exposure in relation to gastric adenocarcinoma development. *Eur J Cancer* 2008;44:1007-14.

Rutegård M, **Lagergren J**, Rouvelas I, Lindblad M, Blazeby JM, Viklund P. A Population-based study of surgical factors in relation to health-related quality of life after esophageal cancer resection. *Br J Surg* 2008;95:592-601.

Nordenstedt H, Zheng Z, Ye W, Pedersen N, **Lagergren J**. Postmenopausal hormone therapy as a risk factor for gastroesophageal reflux symptoms among female twins. *Gastroenterology* 2008;134:921-8.

Sjödahl K, Jia C, Vatten L, Nilsen T, Hveem K, **Lagergren J**. Body mass and physical activity and risk of gastric cancer in a population-based cohort study in Norway. *Cancer Epidemiol Biomarkers Prev* 2008;17:135-40.

Jansson C, Nordenstedt H, Johansson S, Wallander M, Johnsen R, Hveem K, **Lagergren J**. Severe symptoms of gastro-oesophageal reflux disease are associated with cardiovascular disease and other gastrointestinal symptoms, but not diabetes: a population-based study. *Aliment Pharmacol Ther* 2008;27:58-65.

Viklund P, **Lagergren J**. A care pathway for patients with esophageal cancer. *Eur J Cancer Care* 2007;16:533-8.

Jansson C, Nordenstedt H, Wallander M, Johansson S, Johnsen R, Hveem K, **Lagergren J**. Severe gastro-oesophageal reflux symptoms in relation to anxiety, depression and coping in a population-based study. *Aliment Pharmacol Ther* 2007;26:683-91.

Jansson C, Nordenstedt H, Johansson S, Wallander M, Johnsen R, Hveem K, **Lagergren J**. Relation between gastroesophageal reflux symptoms and socioeconomic factors: A population-based study (the HUNT study). *Clin Gastroenterol Hepatol* 2007;5:1029-34.

Martin L, **Lagergren J**, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. *Br J Surg* 2007;94:1496-500.

Lagergren J. Body composition and Barrett's esophagus. *Gastroenterology* 2007;133:343-5.

Lagergren J. Body measures in relation to gastro-oesophageal reflux. *Gut* 2007;56:741-2.

Martin L, **Lagergren J**, Lindblad M, Rouvelas I, Viklund P. The influence of needle catheter jejunostomy on weight development after oesophageal cancer surgery in a population-based study. *Eur J Surg Oncol* 2007; 33:713-7.

Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, **Lagergren J**. Impact of hospital volume on long-term survival after esophageal cancer surgery. *JAMA Surg* 2007;142:113-7.

Sjödahl K, Jansson C, Bergdahl IA, Adami J, Boffetta P, **Lagergren J**. Airborne exposures and risk of gastric cancer: a prospective cohort study. *Int J Cancer* 2007;120:2013-8.

Zheng Z, Nordenstedt H, Pedersen NL, **Lagergren J**, Ye W. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. *Gastroenterology* 2007;132:87-95.

Nordenstedt H, Nilsson M, Johnsen R, **Lagergren J**, Hveem K. Helicobacter pylori infection and gastroesophageal reflux in a population-based study (The HUNT Study). *Helicobacter* 2007;12:16-22.

Lagergren J, Viklund P. Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux? *World J Surg* 2007;31:465-9.

Rouvelas I, Jia C, Lindblad M, Viklund P, **Lagergren J**. Surgeon volume and postoperative mortality after oesophagectomy for cancer. *Eur J Surg Oncol* 2007;33:162-8.

Sjödahl K, Lu Y, Vatten L, Ye W, **Lagergren J**. Smoking and alcohol drinking in relation to risk of gastric cancer: A population-based, prospective cohort study. *Int J Cancer* 2007;120:128-32.

Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, **Lagergren J**. Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. *World J Surg* 2006;30:2182-90.

Lagergren J. Etiology and risk factors for esophageal adenocarcinoma: possibilities for chemoprophylaxis? *Best Pract Res Clin Gastroenterol* 2006;20:803-12.

Wenger U, Johnsson E, Lundell L, Arnelo U, **Lagergren J**. An antireflux stent versus conventional stents for palliation of distal esophageal or cardia cancer: a randomized clinical study. *Surg Endosc* 2006;20:1675-80.

Lagergren J, Viklund P, Jansson C. Carbonated soft drinks and risk of esophageal adenocarcinoma: a population-based case-control study. *J Natl Cancer Inst* 2006;98:1158-61.

Lagergren J, Jansson C. Use of tight belts and risk of esophageal adenocarcinoma. *Int J Cancer* 2006;119:2464-6.

Lagergren J, Jansson C, Viklund P. Chewing gum and risk of oesophageal adenocarcinoma: a new hypothesis tested in a population-based study. *Eur J Cancer* 2006;42:2359-62.

Viklund P, Wengström Y, **Lagergren J**. Supportive care for patients with oesophageal and other upper gastrointestinal cancers: The role of a specialist nurse in the team. *Eur J Oncol Nurs* 2006;10:353-63.

Garcia Rodríguez, LA, **Lagergren J**, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. *Gut* 2006;55:1538-44.

Chandanos E, Lindblad M, Chongqi Jia, Rubio C, Ye W, **Lagergren J**. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. *Br J Cancer* 2006;95:118-22.

Viklund P, Wengström Y, Rouvelas I, Lindblad M, **Lagergren J**. Quality of life and persisting symptoms after esophageal cancer surgery. *Eur J Cancer* 2006;42:1407-14.

Akre O, Forssell L, Kaijser M, Noren-Nilsson I, **Lagergren J**, Nyren O, Ekblom A. Perinatal risk factors for cancer of the esophagus and gastric cardia: a nested case-control study. *Cancer Epidemiol Biomarkers Prev* 2006;15:867-71.

Rubio C, Sjödahl K, **Lagergren J**. Lymphocytic esophagitis: A histologic subset of chronic esophagitis. *Am J Clin Pathol* 2006;125:432-7.

Nordenstedt H, Nilsson M, Johansson S, Wallander M, Johnsen R, Hveem K, **Lagergren J**. The relation between gastroesophageal reflux and respiratory symptoms in a population-based study: the Nord-Trøndelag health survey. *Chest* 2006;129:1051-6.

Lagergren J. The controversy around body-mass index, reflux, and risk of oesophageal adenocarcinoma. *Lancet Oncol* 2006;7:347-9.

Ye W, Kumar R, Bacova G, **Lagergren J**, Hemminki K, Nyrén O. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. *Carcinogenesis* 2006;27:1835-41.

Lindblad M, Lindgren A, Ye W, **Lagergren J**. Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. *Ann Surg* 2006;243:479-85.

Viklund P, Lindblad M, Lu M, Ye W, Johansson J, **Lagergren J**. Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden. *Ann Surg* 2006;243:204-11.

Jansson C, Plato N, Johansson ALV, Nyrén O, **Lagergren J**. Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma. *Occup Environ Med* 2006;63:107-12.

Lindblad M, Rodríguez LG, Chandanos E, **Lagergren J**. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. *Br J Cancer* 2006;94:136-41.

Wenger U, Johnsson E, Bergquist H, Nyman J, Ejnell H, **Lagergren J**, Ruth M, Lundell L. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. *Eur J Gastroenterol Hepatol* 2005;17:1369-77.

Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, **Lagergren J**. Survival after surgery for oesophageal cancer: a population-based study. *Lancet Oncol* 2005;6:864-70.

Lagergren J, Jansson C. Sex hormones and oesophageal adenocarcinoma: influence of childbearing? *Br J Cancer* 2005;93:859-61.

Jansson C, Johansson AL, Bergdahl IA, Dickman PW, Plato N, Adami J, Boffetta P, **Lagergren J**. Occupational exposures and risk of esophageal and gastric cardia cancers among male Swedish construction workers. *Cancer Causes Control* 2005;16:755-64.

Jansson C, Johansson ALV, Nyrén O, **Lagergren J**. Socioeconomic factors and risk of esophageal and cardia adenocarcinoma: A nationwide Swedish case-control study. *Cancer Epidemiol Biomarkers Prev* 2005;14:1754-61.

Viklund P, Lindblad M, **Lagergren J**. Influence of surgery-related factors on quality of life after esophageal or cardia cancer resection. *World J Surg* 2005;29:841-8.

Lindblad M, Rodríguez LA, **Lagergren J**. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. *Cancer Causes Control* 2005;16:285-94.

Wenger U, Luo J, Lundell L, **Lagergren J**. A nationwide study of the use of self-expanding stents in patients with esophageal cancer in Sweden. *Endoscopy* 2005;37:329-34.

Lindblad M, **Lagergren J**, Rodríguez LG. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:444-50.

Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? *Gut* 2005;54 Suppl 1:i1-i5.

Lindblad M, Ye W, Rubio C, **Lagergren J**. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. *Cancer Epidemiol Biomarkers Prev* 2004;13:2203-7.

Nilsson M, **Lagergren J**. The relation between body mass and gastro-oesophageal reflux. *Best Pract Res Clin Gastroenterol* 2004;18:1117-23.

Nilsson M, Johnsen R, Ye W, Hveem K, **Lagergren J**. Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. *Scand J Gastroenterology* 2004;39:1040-5.

Nilsson M, Johnsen R, Ye W, Hveem K, **Lagergren J**. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. *Gut* 2004;53:1730-5.

Jansson C, Johansson AL, Jeding K, Dickman PW, Nyrén O, **Lagergren J**. Psychosocial working conditions and the risk of esophageal and gastric cardia cancers. *Eur J Epidemiol* 2004;19:631-41.

Rubio C, **Lagergren J**. Serrated adenomas of the cardia. *Anticancer Res* 2004;24:2113-6.

Lagergren J. Oesophageal cancer and gastro-oesophageal reflux: what is the relationship? *Gut* 2004;53:1064-5.

Ye W, Held M, **Lagergren J**, Engstrand L, Blot WJ, McLaughlin JK, Nyrén O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. *J Natl Cancer Inst* 2004;96:388-96.

Terry P, **Lagergren J**, Wolk A, Steineck G, Nyrén O. Dietary intake of heterocyclic amines and cancers of the esophagus and gastric cardia. *Cancer Epidemiol Biomarkers Prev* 2003;12:940-4.

Rubio CA, **Lagergren J**. Histological features pertinent to local tumour progression in Barrett's adenocarcinoma. *Anticancer Res* 2003;23:3015-8.

Nilsson M, Johnsen R, Ye W, Hveem K, **Lagergren J**. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA* 2003;290:66-72.

Inadomi JM, Sampliner R, **Lagergren J**, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett's esophagus in high-risk patients: A cost-utility analysis. *Ann Intern Med* 2003;138:176-86.

Freedman J, Grybäck P, Lindqvist M, Granström L, **Lagergren J**, Hellström PM, Jacobsson H, Näslund E. Gastric emptying and duodeno-gastro-oesophageal reflux in gastro-oesophageal reflux disease. *Dig Liver Dis* 2002;34:477-83.

- Nilsson M, Lundegårdh G, Ye W, **Lagergren J**. Body mass and reflux oesophagitis: an oestrogen-dependent association? *Scand J Gastroenterology* 2002;37:626-30.
- Ye W, **Lagergren J**, Weiderpass E, Nyrén O, Adami HO, Ekbom A. Alcohol abuse and the risk of pancreatic cancer. *Gut* 2002;51:236-9.
- Sundelöf M, Ye W, Dickman P, **Lagergren J**. Improved survival in both histological types of oesophageal cancer in Sweden. *Int J Cancer* 2002;99:751-4.
- Cameron AJ, **Lagergren J**, Henriksson C, Nyren O, Locke GR, Pedersen NL. Gastroesophageal reflux disease in monozygotic and dizygotic twins. *Gastroenterology* 2002;122:55-9.
- Lagergren J**. Adenocarcinoma of the oesophagus: risk factors and explanations for the increasing incidence. *Int J Cancer* 2002;38-39 Suppl. 13.
- Lagergren J**. Changing epidemiology of reflux disease? *Eur J Gastroenterol Hepatol* 2001;13(suppl):2-3.
- Lagergren J**. Better insight into risk of oesophageal adenocarcinoma. *Eur J Gastroenterol Hepatol* 2001;13(suppl):79-80.
- Ye W, Chow WH, **Lagergren J**, Yin L, Nyrén O. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. *Gastroenterology* 2001;121:1286-93.
- Ye W, Chow WH, **Lagergren J**, Boffetta P, Boman G, Adami HO, Nyrén O. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma. *Br J Cancer* 2001;85:1317-21.
- Rubio CA, Sveander M, **Lagergren J**. Re-adaptation of the esophageal mucosa of rats to protracted stress. *In vivo* 2001;15:413-6.
- Ye W, **Lagergren J**, Nyrén O, Ekbom A. Risk of pancreatic cancer after cholecystectomy: a cohort study in Sweden. *Gut* 2001;49:678-81.
- Terry P, **Lagergren J**, Hansen H, Wolk A, Nyrén O. Fruit and vegetable consumption in the prevention of esophageal and cardia cancers. *Eur J Cancer Prev* 2001;10:365-9.
- Terry P, **Lagergren J**, Wolk A, Nyrén O. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. *Nutr Cancer* 2000;38:186-91.
- Freedman J, Ye W, Näslund E, **Lagergren J**. Association between cholecystectomy and adenocarcinoma of the esophagus. *Gastroenterology* 2001;121:548-53.
- Lagergren J**, Ye W, Ekbom A. Intestinal cancer after cholecystectomy: Is bile involved in carcinogenesis? *Gastroenterology* 2001;121:542-7.
- Terry P, **Lagergren J**, Ye W, Wolk A, Nyrén O. Inverse association between intake of cereal fiber and risk of gastric cardia cancer. *Gastroenterology* 2001;120:387-91.

Terry P, **Lagergren J**, Wolk A, Nyrén O. Drinking hot beverages is not associated with risk of oesophageal cancers in a Western population. *Br J Cancer* 2001;84:120-1.

Lagergren J, Ye W, Ekblom A. No increased risk of breast cancer after cholecystectomy. *Int J Cancer* 2000;88:679-81.

Lagergren J, Ye W, Bergström R, Nyrén O. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. *JAMA* 2000;284:961-2.

Freedman J, **Lagergren J**, Bergström R, Näslund E, Nyrén O. Cholecystectomy, peptic ulcer disease and the risk of adenocarcinoma of the oesophagus and gastric cardia. *Br J Surg* 2000;87:1087-93.

Terry P, **Lagergren J**, Ye W, Nyrén O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. *Int J Cancer* 2000;87:750-4.

Lagergren J, Ye W, Lindgren A, Nyrén O. Heredity and risk of cancer of the esophagus and gastric cardia. *Cancer Epidemiol Biomarkers Prev* 2000;9:757-60.

Lagergren J, Bergström R, Adami HO, Nyrén O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. *Ann Intern Med* 2000;133:165-75.

Lagergren J, Bergström R, Nyrén O. No relation between body mass and gastroesophageal reflux symptoms in a Swedish population based study. *Gut* 2000;47:26-9.

Lagergren J, Bergström R, Lindgren A, Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. *Int J Cancer* 2000;85:340-6.

Näslund E, Freedman J, **Lagergren J**, Stockeld D, Granström L. Three-year results of laparoscopic vertical banded gastroplasty. *Obes Surg* 1999;9:369-73.

Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. *Ann Intern Med* 1999;130:883-90.

Lagergren J, Nyrén O. No association between colon cancer and adenocarcinoma of the oesophagus in a population based cohort study in Sweden. *Gut* 1999;44:819-21.

Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340:825-31.

Lagergren J, Wang Z, Bergström R, Dillner J, Nyrén O. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. *J Natl Cancer Inst* 1999;91:156-62.

Lagergren J, Nyrén O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. *Cancer Epidemiol Biomarkers Prev* 1998;7:913-5.

Lagergren J, Reichard P. Purine deoxyribonucleosides counteract effects of hydroxyurea on deoxyribonucleoside triphosphate pools and DNA synthesis. *Biochem Pharmacol* 1987;36:2985-91.

